| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 90 | 2022 | 1175 | 6.210 |
Why?
|
| Immunosuppressive Agents | 29 | 2021 | 977 | 1.490 |
Why?
|
| Islets of Langerhans Transplantation | 12 | 2021 | 242 | 1.460 |
Why?
|
| Living Donors | 14 | 2022 | 339 | 1.450 |
Why?
|
| Graft Rejection | 39 | 2014 | 1076 | 1.350 |
Why?
|
| Hepatectomy | 12 | 2011 | 172 | 1.330 |
Why?
|
| Liver Diseases | 11 | 2014 | 242 | 1.250 |
Why?
|
| Tacrolimus | 19 | 2014 | 369 | 1.190 |
Why?
|
| Portal Vein | 7 | 2018 | 121 | 1.070 |
Why?
|
| Graft Survival | 31 | 2018 | 907 | 0.990 |
Why?
|
| Tissue Donors | 12 | 2016 | 504 | 0.940 |
Why?
|
| Postoperative Complications | 22 | 2022 | 2301 | 0.890 |
Why?
|
| Liver Neoplasms | 12 | 2010 | 755 | 0.890 |
Why?
|
| Kidney Transplantation | 24 | 2012 | 855 | 0.860 |
Why?
|
| Tissue and Organ Procurement | 10 | 2022 | 358 | 0.810 |
Why?
|
| Surgical Mesh | 4 | 2007 | 124 | 0.810 |
Why?
|
| Pancreas Transplantation | 10 | 2006 | 104 | 0.810 |
Why?
|
| Hepatic Artery | 7 | 2006 | 84 | 0.750 |
Why?
|
| Organ Transplantation | 5 | 2017 | 281 | 0.740 |
Why?
|
| Humans | 160 | 2022 | 89864 | 0.710 |
Why?
|
| Islets of Langerhans | 6 | 2018 | 549 | 0.650 |
Why?
|
| Liver, Artificial | 4 | 2002 | 7 | 0.630 |
Why?
|
| Quality Improvement | 1 | 2022 | 457 | 0.620 |
Why?
|
| Liver Failure | 4 | 2004 | 68 | 0.620 |
Why?
|
| Abdominal Cavity | 2 | 2007 | 18 | 0.570 |
Why?
|
| Adult | 75 | 2021 | 26784 | 0.560 |
Why?
|
| Hernia, Inguinal | 2 | 2006 | 75 | 0.480 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 61 | 0.470 |
Why?
|
| Child | 42 | 2022 | 7233 | 0.460 |
Why?
|
| Muromonab-CD3 | 11 | 1998 | 69 | 0.420 |
Why?
|
| Wounds, Gunshot | 2 | 2021 | 99 | 0.420 |
Why?
|
| Follow-Up Studies | 26 | 2018 | 3670 | 0.420 |
Why?
|
| Insulin-Secreting Cells | 4 | 2019 | 406 | 0.420 |
Why?
|
| Liver | 11 | 2022 | 1211 | 0.420 |
Why?
|
| Sirolimus | 1 | 2014 | 162 | 0.420 |
Why?
|
| Cyclosporine | 10 | 1998 | 238 | 0.410 |
Why?
|
| Hepatocytes | 3 | 2002 | 122 | 0.410 |
Why?
|
| Male | 74 | 2021 | 42614 | 0.400 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 360 | 0.390 |
Why?
|
| Female | 67 | 2022 | 46529 | 0.390 |
Why?
|
| Prostheses and Implants | 2 | 2010 | 125 | 0.380 |
Why?
|
| Intestines | 1 | 2014 | 416 | 0.380 |
Why?
|
| Veterans | 1 | 2011 | 85 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2021 | 565 | 0.360 |
Why?
|
| Obesity | 2 | 2019 | 972 | 0.340 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2014 | 312 | 0.340 |
Why?
|
| Stents | 4 | 2021 | 412 | 0.330 |
Why?
|
| Duodenum | 3 | 2006 | 105 | 0.330 |
Why?
|
| Lysine | 1 | 2010 | 150 | 0.330 |
Why?
|
| Child, Preschool | 26 | 2016 | 3765 | 0.320 |
Why?
|
| Time Factors | 28 | 2015 | 5357 | 0.320 |
Why?
|
| Middle Aged | 47 | 2021 | 26103 | 0.310 |
Why?
|
| Jaundice, Obstructive | 1 | 2008 | 10 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2010 | 399 | 0.300 |
Why?
|
| Crohn Disease | 2 | 2014 | 764 | 0.300 |
Why?
|
| Jejunum | 2 | 2006 | 80 | 0.300 |
Why?
|
| Liver Abscess | 1 | 2007 | 11 | 0.300 |
Why?
|
| Fasting | 2 | 2018 | 162 | 0.300 |
Why?
|
| Silicones | 1 | 2007 | 20 | 0.290 |
Why?
|
| Hemangioma, Cavernous | 1 | 2008 | 69 | 0.290 |
Why?
|
| Treatment Outcome | 20 | 2015 | 8264 | 0.290 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2007 | 14 | 0.290 |
Why?
|
| Kidney | 5 | 2007 | 1148 | 0.290 |
Why?
|
| Health Care Reform | 1 | 2008 | 85 | 0.290 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.290 |
Why?
|
| Minocycline | 1 | 2007 | 15 | 0.290 |
Why?
|
| Duodenal Diseases | 1 | 2007 | 23 | 0.280 |
Why?
|
| Patient Selection | 3 | 2020 | 682 | 0.280 |
Why?
|
| Liver Failure, Acute | 1 | 2007 | 39 | 0.280 |
Why?
|
| Infant | 21 | 2015 | 3187 | 0.270 |
Why?
|
| Diverticulum | 1 | 2007 | 45 | 0.270 |
Why?
|
| Rectal Diseases | 1 | 2006 | 23 | 0.270 |
Why?
|
| Bacterial Infections | 2 | 2005 | 184 | 0.270 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2005 | 41 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 3 | 2007 | 798 | 0.260 |
Why?
|
| Adolescent | 30 | 2021 | 9327 | 0.260 |
Why?
|
| Colonic Diseases | 1 | 2006 | 61 | 0.260 |
Why?
|
| Antiviral Agents | 3 | 2022 | 482 | 0.260 |
Why?
|
| Tendons | 1 | 2006 | 44 | 0.260 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2005 | 9 | 0.260 |
Why?
|
| Hepatic Veins | 2 | 2002 | 26 | 0.250 |
Why?
|
| Foreign Bodies | 1 | 2006 | 66 | 0.250 |
Why?
|
| Bioprosthesis | 1 | 2005 | 39 | 0.250 |
Why?
|
| Anesthesia, Local | 1 | 2005 | 27 | 0.250 |
Why?
|
| Ileostomy | 1 | 2005 | 29 | 0.250 |
Why?
|
| Prosthesis-Related Infections | 1 | 2005 | 61 | 0.250 |
Why?
|
| Retrospective Studies | 30 | 2016 | 9185 | 0.240 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2002 | 99 | 0.240 |
Why?
|
| Transplantation, Homologous | 17 | 2013 | 995 | 0.230 |
Why?
|
| Prosthesis Implantation | 1 | 2005 | 129 | 0.230 |
Why?
|
| Cyclic GMP | 1 | 2004 | 62 | 0.230 |
Why?
|
| Catheterization | 1 | 2005 | 237 | 0.230 |
Why?
|
| Pancreatitis, Chronic | 2 | 2015 | 61 | 0.220 |
Why?
|
| Survival Rate | 15 | 2014 | 1898 | 0.220 |
Why?
|
| Pancreas | 4 | 2018 | 251 | 0.220 |
Why?
|
| Morbidity | 2 | 2022 | 149 | 0.220 |
Why?
|
| Prospective Studies | 12 | 2021 | 4322 | 0.220 |
Why?
|
| Bile Ducts | 2 | 2002 | 60 | 0.210 |
Why?
|
| Ultrasonography, Doppler | 2 | 2002 | 85 | 0.210 |
Why?
|
| Extracorporeal Circulation | 1 | 2002 | 37 | 0.210 |
Why?
|
| Blood Loss, Surgical | 2 | 2001 | 116 | 0.210 |
Why?
|
| China | 4 | 2015 | 235 | 0.200 |
Why?
|
| Cholecystectomy | 1 | 2002 | 22 | 0.200 |
Why?
|
| Thrombosis | 4 | 2002 | 302 | 0.200 |
Why?
|
| Cannabidiol | 1 | 2022 | 8 | 0.200 |
Why?
|
| Pancreatectomy | 3 | 2018 | 164 | 0.200 |
Why?
|
| Rectus Abdominis | 2 | 2013 | 40 | 0.190 |
Why?
|
| Abdominal Wall | 2 | 2013 | 30 | 0.190 |
Why?
|
| Hepatitis C | 4 | 2012 | 174 | 0.190 |
Why?
|
| Mortality | 1 | 2022 | 149 | 0.190 |
Why?
|
| Head Injuries, Penetrating | 1 | 2022 | 55 | 0.190 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 265 | 0.190 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 185 | 0.180 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 14 | 0.180 |
Why?
|
| Hypertension, Portal | 3 | 1998 | 46 | 0.180 |
Why?
|
| Prognosis | 8 | 2018 | 3789 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 102 | 0.170 |
Why?
|
| Perfusion | 2 | 2022 | 253 | 0.170 |
Why?
|
| Policy | 1 | 2020 | 35 | 0.170 |
Why?
|
| Biliary Tract Diseases | 2 | 1997 | 36 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 1 | 2022 | 237 | 0.170 |
Why?
|
| Prisoners | 2 | 2011 | 45 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 145 | 0.170 |
Why?
|
| Waiting Lists | 4 | 2007 | 186 | 0.170 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 95 | 0.160 |
Why?
|
| Hepatitis B | 5 | 2010 | 76 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2021 | 189 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 449 | 0.160 |
Why?
|
| Reperfusion Injury | 2 | 1997 | 144 | 0.160 |
Why?
|
| Reoperation | 15 | 1999 | 604 | 0.150 |
Why?
|
| Informed Consent | 3 | 2011 | 275 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 158 | 0.150 |
Why?
|
| Health Policy | 2 | 2011 | 188 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2005 | 777 | 0.150 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 102 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2022 | 433 | 0.150 |
Why?
|
| Anastomosis, Surgical | 4 | 2006 | 275 | 0.150 |
Why?
|
| HIV Infections | 3 | 2012 | 847 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 3 | 2010 | 414 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 255 | 0.150 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 1998 | 11 | 0.150 |
Why?
|
| Urea | 1 | 1998 | 59 | 0.150 |
Why?
|
| Ammonia | 1 | 1998 | 39 | 0.150 |
Why?
|
| Donor Selection | 2 | 2018 | 76 | 0.150 |
Why?
|
| Cultural Characteristics | 2 | 2015 | 18 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2019 | 776 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2008 | 2676 | 0.140 |
Why?
|
| Gallbladder | 1 | 1997 | 31 | 0.140 |
Why?
|
| Occlusive Dressings | 1 | 1996 | 7 | 0.140 |
Why?
|
| Chicago | 5 | 2021 | 1431 | 0.140 |
Why?
|
| Laparotomy | 2 | 2007 | 68 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 1996 | 74 | 0.140 |
Why?
|
| Cyclosporins | 6 | 1991 | 58 | 0.140 |
Why?
|
| Liver Cirrhosis | 4 | 2010 | 257 | 0.140 |
Why?
|
| Biliary Atresia | 4 | 1995 | 22 | 0.130 |
Why?
|
| Cholangiocarcinoma | 3 | 2010 | 81 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 5 | 2004 | 1394 | 0.130 |
Why?
|
| Stomach | 2 | 2006 | 111 | 0.130 |
Why?
|
| Tissue Preservation | 1 | 2015 | 14 | 0.120 |
Why?
|
| Gift Giving | 1 | 2015 | 5 | 0.120 |
Why?
|
| Social Control, Formal | 1 | 2015 | 12 | 0.120 |
Why?
|
| Volition | 1 | 2015 | 15 | 0.120 |
Why?
|
| Steroids | 1 | 1996 | 173 | 0.120 |
Why?
|
| Pentanoic Acids | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2013 | 51 | 0.120 |
Why?
|
| Biotin | 1 | 2014 | 45 | 0.120 |
Why?
|
| United States | 8 | 2021 | 7094 | 0.120 |
Why?
|
| Universities | 1 | 2015 | 145 | 0.110 |
Why?
|
| International Agencies | 1 | 2014 | 34 | 0.110 |
Why?
|
| Mixed Tumor, Malignant | 1 | 1994 | 4 | 0.110 |
Why?
|
| Surface-Active Agents | 1 | 2014 | 61 | 0.110 |
Why?
|
| Body Height | 1 | 2014 | 100 | 0.110 |
Why?
|
| Carcinosarcoma | 1 | 1994 | 21 | 0.110 |
Why?
|
| Mycophenolic Acid | 3 | 1998 | 84 | 0.110 |
Why?
|
| Colectomy | 3 | 2007 | 173 | 0.110 |
Why?
|
| Transplantation Immunology | 1 | 2014 | 81 | 0.110 |
Why?
|
| Health Behavior | 1 | 2015 | 185 | 0.110 |
Why?
|
| Aged | 14 | 2016 | 19230 | 0.110 |
Why?
|
| Surgical Flaps | 2 | 2013 | 250 | 0.110 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2007 | 79 | 0.110 |
Why?
|
| Morphogenesis | 1 | 2014 | 207 | 0.110 |
Why?
|
| Heart Transplantation | 6 | 2008 | 728 | 0.110 |
Why?
|
| Cadaver | 4 | 2002 | 186 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2013 | 70 | 0.100 |
Why?
|
| Liver Function Tests | 3 | 1997 | 92 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 17 | 0.100 |
Why?
|
| International Cooperation | 2 | 2011 | 127 | 0.100 |
Why?
|
| Opportunistic Infections | 2 | 2010 | 60 | 0.100 |
Why?
|
| Capital Punishment | 1 | 2011 | 3 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 97 | 0.100 |
Why?
|
| Rats, Inbred Lew | 3 | 2010 | 197 | 0.100 |
Why?
|
| Animals | 13 | 2022 | 27516 | 0.100 |
Why?
|
| Coinfection | 1 | 2012 | 62 | 0.100 |
Why?
|
| Hepatoblastoma | 2 | 2010 | 12 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 493 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2013 | 171 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2013 | 346 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 91 | 0.100 |
Why?
|
| Liver Regeneration | 1 | 2011 | 36 | 0.090 |
Why?
|
| Platelet Count | 1 | 2011 | 93 | 0.090 |
Why?
|
| Tumor Virus Infections | 2 | 2005 | 83 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 1994 | 684 | 0.090 |
Why?
|
| Death | 1 | 2011 | 89 | 0.090 |
Why?
|
| Fascia | 1 | 2010 | 31 | 0.090 |
Why?
|
| Survival Analysis | 8 | 2012 | 1497 | 0.090 |
Why?
|
| Hyperoxaluria | 1 | 2010 | 26 | 0.090 |
Why?
|
| Hepatic Encephalopathy | 2 | 2001 | 39 | 0.090 |
Why?
|
| Hemangioendothelioma | 1 | 2010 | 9 | 0.090 |
Why?
|
| Incidence | 6 | 2012 | 1600 | 0.090 |
Why?
|
| Capsules | 1 | 2010 | 37 | 0.090 |
Why?
|
| Alginates | 1 | 2010 | 16 | 0.090 |
Why?
|
| Polylysine | 1 | 2010 | 34 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1983 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 1991 | 700 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 539 | 0.090 |
Why?
|
| Costs and Cost Analysis | 3 | 2021 | 153 | 0.090 |
Why?
|
| Transplantation Tolerance | 1 | 2011 | 138 | 0.090 |
Why?
|
| Enterococcus | 2 | 2001 | 35 | 0.080 |
Why?
|
| Antibodies | 4 | 2000 | 353 | 0.080 |
Why?
|
| Radiography | 3 | 2007 | 808 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1929 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1989 | 395 | 0.080 |
Why?
|
| Young Adult | 6 | 2019 | 6389 | 0.080 |
Why?
|
| Resuscitation | 2 | 2022 | 111 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2011 | 449 | 0.080 |
Why?
|
| ABO Blood-Group System | 2 | 2008 | 58 | 0.080 |
Why?
|
| Age Factors | 5 | 2019 | 1880 | 0.080 |
Why?
|
| Drug Compounding | 1 | 2010 | 84 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2018 | 0.080 |
Why?
|
| Sarcoma | 1 | 2010 | 219 | 0.080 |
Why?
|
| Illinois | 2 | 2002 | 485 | 0.080 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2008 | 35 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 124 | 0.080 |
Why?
|
| Documentation | 1 | 2009 | 103 | 0.080 |
Why?
|
| Amikacin | 1 | 2007 | 5 | 0.080 |
Why?
|
| C-Peptide | 2 | 2018 | 179 | 0.080 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 21 | 0.080 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 29 | 0.070 |
Why?
|
| Organ Preservation | 3 | 2022 | 119 | 0.070 |
Why?
|
| Guanine | 1 | 2008 | 207 | 0.070 |
Why?
|
| Kidney Diseases | 3 | 2005 | 320 | 0.070 |
Why?
|
| Rats | 6 | 2010 | 4048 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2001 | 111 | 0.070 |
Why?
|
| Body Weight | 2 | 2014 | 453 | 0.070 |
Why?
|
| Biopsy | 5 | 1999 | 1184 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 2007 | 99 | 0.070 |
Why?
|
| Iliac Vein | 1 | 2007 | 32 | 0.070 |
Why?
|
| Creatinine | 5 | 1999 | 294 | 0.070 |
Why?
|
| Health Care Rationing | 2 | 2004 | 83 | 0.070 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 35 | 0.070 |
Why?
|
| Prednisone | 5 | 1998 | 255 | 0.070 |
Why?
|
| Iliac Artery | 1 | 2007 | 41 | 0.070 |
Why?
|
| Splenic Artery | 1 | 2006 | 11 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2007 | 69 | 0.070 |
Why?
|
| Aorta, Abdominal | 1 | 2006 | 59 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2010 | 384 | 0.070 |
Why?
|
| Length of Stay | 3 | 2001 | 745 | 0.070 |
Why?
|
| Pressure | 1 | 2007 | 166 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2006 | 36 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2009 | 306 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1066 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2007 | 203 | 0.070 |
Why?
|
| Polypropylenes | 1 | 2005 | 23 | 0.060 |
Why?
|
| Blood Glucose | 3 | 2018 | 837 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2019 | 2324 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 88 | 0.060 |
Why?
|
| Necrosis | 1 | 2006 | 210 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 1998 | 231 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 347 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2006 | 116 | 0.060 |
Why?
|
| Risk Factors | 10 | 2012 | 5548 | 0.060 |
Why?
|
| Drug Resistance | 2 | 1996 | 232 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2008 | 958 | 0.060 |
Why?
|
| BK Virus | 1 | 2005 | 24 | 0.060 |
Why?
|
| Polyomavirus Infections | 1 | 2005 | 29 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2005 | 77 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1180 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 200 | 0.060 |
Why?
|
| Acute Disease | 4 | 1999 | 846 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2007 | 291 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2018 | 2886 | 0.060 |
Why?
|
| California | 3 | 1997 | 146 | 0.060 |
Why?
|
| Mice | 4 | 2022 | 11846 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 198 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1227 | 0.060 |
Why?
|
| Cell Separation | 1 | 2004 | 199 | 0.060 |
Why?
|
| Hospitals, University | 3 | 1999 | 196 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 194 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 206 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2004 | 314 | 0.050 |
Why?
|
| Canada | 2 | 2007 | 208 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 168 | 0.050 |
Why?
|
| Organ Size | 2 | 2014 | 372 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2005 | 256 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 154 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1998 | 270 | 0.050 |
Why?
|
| Temperature | 1 | 2004 | 409 | 0.050 |
Why?
|
| Virus Replication | 2 | 2022 | 326 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2000 | 979 | 0.050 |
Why?
|
| Antilymphocyte Serum | 5 | 2004 | 70 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2002 | 88 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 198 | 0.050 |
Why?
|
| Bilirubin | 3 | 1999 | 131 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2010 | 1542 | 0.050 |
Why?
|
| A549 Cells | 1 | 2022 | 42 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2002 | 70 | 0.050 |
Why?
|
| Drug Administration Schedule | 4 | 1998 | 865 | 0.050 |
Why?
|
| Vero Cells | 1 | 2022 | 103 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2022 | 40 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 6779 | 0.050 |
Why?
|
| Insulin | 3 | 2018 | 1148 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2002 | 222 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 90 | 0.050 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2002 | 57 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2001 | 18 | 0.050 |
Why?
|
| Respiratory Insufficiency | 2 | 2001 | 162 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2022 | 86 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2022 | 93 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 127 | 0.050 |
Why?
|
| Constriction | 1 | 2001 | 27 | 0.050 |
Why?
|
| Biological Availability | 2 | 1998 | 91 | 0.050 |
Why?
|
| Bile | 2 | 2001 | 58 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2022 | 94 | 0.050 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2001 | 19 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1858 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 232 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 40 | 0.050 |
Why?
|
| Foreign-Body Migration | 1 | 2001 | 39 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2000 | 24 | 0.050 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2000 | 34 | 0.040 |
Why?
|
| Heart Rate | 1 | 2002 | 498 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 242 | 0.040 |
Why?
|
| Immunotherapy | 2 | 1999 | 693 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2000 | 45 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2001 | 270 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 368 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 1997 | 91 | 0.040 |
Why?
|
| Hepatitis, Alcoholic | 1 | 1999 | 16 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 154 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2010 | 296 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 1999 | 47 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 816 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2000 | 312 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2002 | 905 | 0.040 |
Why?
|
| Emulsions | 1 | 1998 | 19 | 0.040 |
Why?
|
| North America | 1 | 2018 | 188 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 111 | 0.040 |
Why?
|
| Cytokines | 1 | 2022 | 811 | 0.040 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 1998 | 4 | 0.040 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 1998 | 4 | 0.040 |
Why?
|
| Citrulline | 1 | 1998 | 10 | 0.040 |
Why?
|
| Communication Disorders | 1 | 1998 | 7 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 1607 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2001 | 1350 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2001 | 431 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 689 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 983 | 0.040 |
Why?
|
| Microcephaly | 1 | 1998 | 76 | 0.040 |
Why?
|
| Alcoholism | 1 | 1999 | 180 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1998 | 51 | 0.040 |
Why?
|
| Vancomycin | 1 | 1998 | 73 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 227 | 0.040 |
Why?
|
| Coccidioidomycosis | 1 | 1997 | 8 | 0.040 |
Why?
|
| Dosage Forms | 1 | 1996 | 7 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1714 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1999 | 372 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 1998 | 189 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1996 | 64 | 0.030 |
Why?
|
| Syndrome | 1 | 1997 | 450 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2001 | 480 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1996 | 120 | 0.030 |
Why?
|
| Oxygen | 1 | 2001 | 745 | 0.030 |
Why?
|
| Quality of Life | 3 | 1996 | 1680 | 0.030 |
Why?
|
| Situs Inversus | 1 | 1995 | 15 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1074 | 0.030 |
Why?
|
| Pancreatic Function Tests | 1 | 2015 | 7 | 0.030 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1214 | 0.030 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2015 | 25 | 0.030 |
Why?
|
| Altruism | 1 | 2015 | 34 | 0.030 |
Why?
|
| Public Opinion | 1 | 2015 | 44 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1996 | 666 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1999 | 22 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Succinimides | 1 | 2014 | 12 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1996 | 299 | 0.030 |
Why?
|
| Streptavidin | 1 | 2014 | 14 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 82 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 319 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 785 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 200 | 0.030 |
Why?
|
| Celiac Plexus | 1 | 1993 | 3 | 0.030 |
Why?
|
| Hepatitis B virus | 2 | 2008 | 45 | 0.030 |
Why?
|
| Nerve Compression Syndromes | 1 | 1993 | 19 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1994 | 45 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 374 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 37 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2011 | 871 | 0.030 |
Why?
|
| Family | 1 | 1995 | 325 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 590 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 426 | 0.030 |
Why?
|
| Recurrence | 4 | 1998 | 1144 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 51 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 191 | 0.030 |
Why?
|
| Hemorrhage | 2 | 2000 | 287 | 0.030 |
Why?
|
| Azathioprine | 3 | 1998 | 124 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 20 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 1989 | 1221 | 0.030 |
Why?
|
| Cholestasis | 1 | 1992 | 45 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 1995 | 384 | 0.020 |
Why?
|
| Medical Tourism | 1 | 2011 | 5 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 91 | 0.020 |
Why?
|
| CD3 Complex | 2 | 1989 | 134 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 171 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 206 | 0.020 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 8 | 0.020 |
Why?
|
| Drainage | 3 | 1998 | 165 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 178 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1998 | 582 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2011 | 91 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2012 | 131 | 0.020 |
Why?
|
| Colitis, Ulcerative | 2 | 2013 | 750 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 33 | 0.020 |
Why?
|
| Algorithms | 2 | 2014 | 1908 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 1998 | 744 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 1998 | 785 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 68 | 0.020 |
Why?
|
| Brain Death | 1 | 2011 | 83 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 44 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1799 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 92 | 0.020 |
Why?
|
| Hypertonic Solutions | 1 | 1990 | 17 | 0.020 |
Why?
|
| Abdomen | 1 | 2010 | 124 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 1990 | 31 | 0.020 |
Why?
|
| Solutions | 1 | 1990 | 86 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 996 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 1994 | 1183 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1990 | 171 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1729 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 1999 | 9 | 0.020 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1989 | 12 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1989 | 44 | 0.020 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 1988 | 3 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 327 | 0.020 |
Why?
|
| Rupture | 1 | 2008 | 61 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1988 | 41 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 854 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 848 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 2 | 1998 | 10 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 263 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 1998 | 2498 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1994 | 1532 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3250 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 538 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 1255 | 0.020 |
Why?
|
| Rats, Inbred BUF | 3 | 1991 | 4 | 0.020 |
Why?
|
| Los Angeles | 2 | 1996 | 28 | 0.020 |
Why?
|
| Angiography | 1 | 2006 | 208 | 0.020 |
Why?
|
| Crotonates | 1 | 2005 | 12 | 0.020 |
Why?
|
| Toluidines | 1 | 2005 | 18 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 1995 | 1704 | 0.020 |
Why?
|
| Hydroxybutyrates | 1 | 2005 | 27 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2005 | 59 | 0.020 |
Why?
|
| Nitriles | 1 | 2005 | 156 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 67 | 0.010 |
Why?
|
| Urinary Bladder | 2 | 1996 | 248 | 0.010 |
Why?
|
| Esophageal and Gastric Varices | 2 | 1998 | 35 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2004 | 98 | 0.010 |
Why?
|
| Small-Area Analysis | 1 | 2003 | 8 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 1134 | 0.010 |
Why?
|
| Health Priorities | 1 | 2003 | 22 | 0.010 |
Why?
|
| Geography | 1 | 2003 | 227 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2000 | 2000 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 434 | 0.010 |
Why?
|
| Environmental Microbiology | 1 | 2001 | 22 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1998 | 239 | 0.010 |
Why?
|
| Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
| Government Regulation | 1 | 2001 | 50 | 0.010 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2001 | 10 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 576 | 0.010 |
Why?
|
| Hamartoma | 1 | 2001 | 35 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2001 | 244 | 0.010 |
Why?
|
| Hemangioma | 1 | 2001 | 64 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 150 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1990 | 312 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 2 | 1990 | 44 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 216 | 0.010 |
Why?
|
| Alanine Transaminase | 2 | 1990 | 72 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 2 | 1990 | 75 | 0.010 |
Why?
|
| Cysts | 1 | 2001 | 106 | 0.010 |
Why?
|
| Feces | 1 | 2001 | 332 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 236 | 0.010 |
Why?
|
| Risk | 1 | 2001 | 657 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 692 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 250 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 324 | 0.010 |
Why?
|
| Adenoma | 1 | 2001 | 250 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1998 | 25 | 0.010 |
Why?
|
| Pregnancy | 2 | 2001 | 3040 | 0.010 |
Why?
|
| Pneumonia | 1 | 2000 | 183 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 75 | 0.010 |
Why?
|
| Aminosalicylic Acids | 1 | 1998 | 41 | 0.010 |
Why?
|
| Gallbladder Diseases | 1 | 1998 | 23 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 345 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2000 | 275 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1997 | 42 | 0.010 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 1998 | 69 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 1998 | 98 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
| Fluconazole | 1 | 1997 | 11 | 0.010 |
Why?
|
| Fibrin | 1 | 1997 | 86 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
| Capillaries | 1 | 1997 | 90 | 0.010 |
Why?
|
| Bacteremia | 1 | 1998 | 103 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1997 | 122 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1996 | 137 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1997 | 278 | 0.010 |
Why?
|
| Neutrophils | 1 | 1997 | 311 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1995 | 57 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 1995 | 87 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 469 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1996 | 230 | 0.010 |
Why?
|
| Safety | 1 | 1995 | 145 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1997 | 357 | 0.010 |
Why?
|
| Extremities | 1 | 1995 | 173 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1994 | 71 | 0.010 |
Why?
|
| Emergencies | 1 | 1995 | 122 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 231 | 0.010 |
Why?
|
| Ischemia | 1 | 1995 | 253 | 0.010 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 1993 | 33 | 0.010 |
Why?
|
| Choledochostomy | 1 | 1992 | 8 | 0.010 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1992 | 14 | 0.010 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 1992 | 26 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1992 | 60 | 0.010 |
Why?
|
| Dilatation | 1 | 1992 | 48 | 0.010 |
Why?
|
| Immune Sera | 1 | 1991 | 52 | 0.010 |
Why?
|
| Adenoma, Bile Duct | 1 | 1990 | 4 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 1990 | 38 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 26 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1990 | 40 | 0.010 |
Why?
|
| Raffinose | 1 | 1990 | 23 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1990 | 224 | 0.010 |
Why?
|
| Allopurinol | 1 | 1990 | 77 | 0.010 |
Why?
|
| Glutathione | 1 | 1990 | 108 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 716 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 1008 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 270 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1990 | 899 | 0.000 |
Why?
|
| Occupations | 1 | 1988 | 25 | 0.000 |
Why?
|
| Adenosine | 1 | 1990 | 240 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1988 | 205 | 0.000 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1988 | 260 | 0.000 |
Why?
|